[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.204.227.250. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 2,154
Citations 0
News From the Food and Drug Administration
August 6, 2019

Combination Approved for Advanced Multiple Myeloma

JAMA. 2019;322(5):393. doi:10.1001/jama.2019.11155

The FDA granted accelerated approval to the nuclear transport inhibitor selinexor in combination with the corticosteroid dexamethasone for patients with relapsed or refractory multiple myeloma. Marketed as Xpovio, the drug is indicated for patients treated with at least 4 prior therapies whose disease has developed resistance to other treatments, including at least 2 proteasome inhibitors, 2 immunomodulatory agents, and an anti-CD38 monoclonal antibody.

×